News

Gilead Sciences, a biopharmaceutical company, has started enrolling patients in a Phase II clinical trial of its investigational integrase-based, single-tablet, once-daily regimen of elvitegravir, GS 9350 and Truvada

Icagen, a biopharmaceutical company, has presented positive results from its Phase I program for ICA-105665, the company’s lead drug candidate for the treatment of epilepsy and neuropathic pain.

Dendreon, a biotechnology company, has reported positive data from its Protect or P-11 Phase III study suggesting that Provenge induces long-term memory immune responses that are durable and

Revenues for the fourth quarter of 2008 were $843,000, an increase of 231% from the $255,000 reported for the fourth quarter of 2007. Revenues for the full year

For the first quarter of 2009, Illumina reported gross margin of 66.4% compared with 60.2% in the comparable period of 2008. Excluding the effect of the amortization of

Vion Pharmaceuticals has reported that the new drug application for its lead oncology therapeutic Onrigin injection has been accepted for review by the FDA. The NDA presents data

Can-Fite, an Israeli biotechnology company, has reported that, following the approval by the Israel Ministry of Health and Rabin MC Ethics Committee, a Phase I/II clinical trial with

Intuitive Surgical, a developer and marketer of robotic technologies, has reported a net income of $28.14m, or $0.72 per diluted share, for the first quarter of 2009, compared

Sud-Chemie, a specialty chemicals company headquartered in Munich, Germany signed an agreement with BASF to acquire BASF’s production site for synthesis gas (syngas) catalysts at Nanjing, China. The